What do Cochrane systematic reviews say about the management of irritable bowel syndrome?
Palavras-chave:
Irritable bowel syndrome, Colonic diseases, functional, Evidence-based medicine, Evidence-based practiceResumo
BACKGROUND: Irritable bowel syndrome (IBS) is a clinical disorder associated with high socioeconomic burden. Despite its importance, management of IBS remains difficult and several interventions have been hypothesized as beneficial for this condition. This study identified and summarized all Cochrane systemat-ic reviews (SRs) about the effects of interventions for managing IBS patients. DESIGN AND SETTING: Review of systematic reviews, carried out in the Discipline of Evidence-Based Medicine, Escola Paulista de Medicina (EPM), Universidade Federal de São Paulo (UNIFESP). METHODS: Review of Cochrane SRs addressing interventions for IBS. RESULTS: We included six SRs assessing acupuncture, bulking agents, antispasmodics, antidepressants, herbal medicines, homeopathy, hypnotherapy and psychological therapy for IBS. The certainty of evi-dence ranged from unknown to moderate, mainly due to imprecision in the estimates and high risk of bias from the primary studies included. There was moderate certainty of evidence that acupuncture had no important benefit regarding improvement of symptoms and quality of life, compared with sham acu-puncture. There was also very low certainty of evidence that homeopathic asafoetida, used alone or in association with nux, was better than placebo regarding self-reported overall improvement. CONCLUSION: There was moderate certainty of evidence that acupuncture had no important benefit regarding improvement of symptoms and quality of life. Further well-designed and well-conducted ran-domized clinical trials are needed in order to reduce the uncertainties regarding the most commonly used interventions for patients with IBS.
Downloads
Referências
Canavan C, West J, Card T. The epidemiology of irritable bowel syndrome. Clin Epidemiol. 2014;6:71-80. PMID: 24523597; doi: 10.2147/CLEP.S40245.
Cremonini F, Talley NJ. Irritable bowel syndrome: epidemiology, natural history, health care seeking and emerging risk factors. Gastroenterol Clin North Am. 2005;34(2):189-204. PMID: 15862929; doi: 10.1016/j. gtc.2005.02.008.
Schmulson MJ, Drossman DA. What Is New in Rome IV. J Neurogastroenterol Motil. 2017;23(2):151-63. PMID: 28274109; doi: 10.5056/jnm16214.
Whitehead WE, Palsson O, Jones KR. Systematic review of the comorbidity of irritable bowel syndrome with other disorders: what are the causes and implications? Gastroenterology. 2002;122(4):1140-56. PMID: 11910364.
Ford AC, Lacy BE, Talley NJ. Irritable Bowel Syndrome. N Engl J Med. 2017;29;376(26):2566-78. PMID: 28657875; doi: 10.1056/NEJMra1607547.
Nellesen D, Yee K, Chawla A, Lewis BE, Carson RT. A systematic review of the economic and humanistic burden of illness in irritable bowel syndrome and chronic constipation. J Manag Care Pharm. 2013;19(9):755-64. PMID: 24156644; doi: 10.18553/jmcp.2013.19.9.755.
Zhang F, Xiang W, Li CY, Li SC. Economic burden of irritable bowel syndrome in China. World J Gastroenterol. 2016;22(47):10450-60. PMID: 28058026; doi: 10.3748/wjg.v22.i47.10450.
Canavan C, West J, Card T. Review article: the economic impact of the irritable bowel syndrome. Aliment Pharmacol Ther. 2014;40(9):1023-34. PMID: 25199904; doi: 10.1111/apt.12938.
Halland M, Saito YA. Irritable bowel syndrome: new and emerging
treatments. BMJ. 2015;350:h1622. PMID: 26088265; doi: 10.1136/ bmj.h1622.
Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. BMJ. 2004;328(7454):1490. PMID: 15205295; doi: 10.1136/bmj.328.7454.1490.
Manheimer E, Cheng K, Wieland LS, et al. Acupuncture for treatment of irritable bowel syndrome. Cochrane Database Syst Rev. 2012;(5):CD005111. PMID: 22592702; doi: 10.1002/14651858. CD005111.pub3.
Ruepert L, Quartero AO, de Wit NJ, et al. Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev. 2011;(8):CD003460. PMID: 21833945; doi: 10.1002/14651858.CD003460.pub3.
Liu JP, Yang M, Liu YX, Wei M, Grimsgaard S. Herbal medicines for treatment of irritable bowel syndrome. Cochrane Database Syst Rev. 2006;(1):CD004116. PMID: 16437473; doi: 10.1002/14651858. CD004116.pub2.
Peckham EJ, Nelson EA, Greenhalgh J, et al. Homeopathy for treatment of irritable bowel syndrome. Cochrane Database Syst Rev. 2013;(11):CD009710. PMID: 24222383; doi: 10.1002/14651858. CD009710.pub2.
Webb AN, Kukuruzovic RH, Catto‐Smith AG, Sawyer SM. Hypnotherapy for treatment of irritable bowel syndrome. Cochrane Database Syst Rev. 2007;(4):CD005110. PMID: 17943840; doi: 10.1002/14651858. CD005110.pub2.
Zijdenbos IL, de Wit NJ, van der Heijden GJ, Rubin G, Quartero AO. Psychological treatments for the management of irritable bowel syndrome. Cochrane Database Syst Rev. 2009;(1):CD006442. PMID: 19160286; doi: 10.1002/14651858.CD006442.pub2.
Francis CY, Morris J, Whorwell PJ. The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther. 1997;11(2):395-402. PMID: 9146781.
Patrick DL, Drossman DA, Frederick IO, DiCesare J, Puder KL. Quality of life in persons with irritable bowel syndrome: development and validation of a new measure. Dig Dis Sci. 1998;43(2):400-11. PMID: 9512138.
Blanchard EE, Schwartz SP. Clinically significant changes in behavioral medicine. Behav Assess. 1988;10(2):171‐88.
Wang P, Tang X, Wu T, Liu G. Probiotic agents for the treatment of diarrhoea‐predominant irritable bowel syndrome. Cochrane Database Syst Rev. 2006;(2):CD005985. doi: 10.1002/14651858.CD005985.
Barajas‐Nava LA, Consuelo Sánchez A, Castilla‐Peon MF, Pizarro‐ Castellanos MP, Vazquez Frias R. Probiotics for the treatment of irritable bowel syndrome in children. Cochrane Database Syst Rev. 2018;(8):CD013095. doi: 10.1002/14651858.CD013095.
Goldenberg JZ, Brignall M, Hamilton M, Beardsley J, Lichtenstein B. Biofeedback for treatment of irritable bowel syndrome. Cochrane Database Syst Rev. 2017;(1):CD012530. doi: 10.1002/14651858. CD012530.
Nunan D, Boughtflower J, Roberts NW, Mahtani KR. Physical activity for treatment of irritable bowel syndrome. Cochrane Database Syst Rev. 2015;(1):CD011497. doi: 10.1002/14651858.CD011497.
Corsetti M, Tack J. Linaclotide: A new drug for the treatment of chronic constipation and irritable bowel syndrome with constipation. United European Gastroenterol J. 2013;1(1):7-20. PMID: 24917937; doi: 10.1177/2050640612474446.
Maltz F, Fidler B. Eluxadoline (Viberzi): A Mu-Opioid Receptor Agonist for the Treatment Of Irritable Bowel Syndrome With Diarrhea. P T. 2017;42(7):438-42. PMID: 28674470.
Mitchell H, Porter J, Gibson PR, Barrett J, Garg M. Review article: implementation of a diet low in FODMAPs for patients with irritable bowel syndrome-directions for future research. Aliment Pharmacol Ther. 2019;49(2):124-139. PMID: 30589971; doi: 10.1111/apt.15079.
Johnsen PH, Hilpüsch F, Cavanagh JP, et al. Faecal microbiota transplantation versus placebo for moderate-to-severe irritable bowel syndrome: a double-blind, randomised, placebo-controlled, parallel-group, single-centre trial. Lancet Gastroenterol Hepatol. 2018;3(1):17-24. PMID: 29100842; doi: 10.1016/S2468-1253(17)30338-2.
Downloads
Publicado
Como Citar
Edição
Seção
Licença
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
